MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgaf655

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2026

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Wolf Jan, Lorenz Katrin, Othman Ahmed E, Beck Anna, Michel Helena M, Grauhan Lea, Elflein Heike, Luffy Maximilian, Eckstein Anja, Lahner Harald, Schittkowski Michael, Horn Maren, Lagrèze Wolf A, Bleul Tim, Pitz Susanne, Vorländer Christian, Pieterse Christelle C, Porter Brian, Clemens Andreas, Draikiwicz Steven, Reinhardt Maximilian, Kahaly George J

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

CONTEXT: Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity.

OBJECTIVE

The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO.

METHODS

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight-threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16.

RESULTS

Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered.

CONCLUSION

Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.

Для цитирования: Wolf Jan, Lorenz Katrin, Othman Ahmed E, Beck Anna, Michel Helena M, Grauhan Lea, Elflein Heike, Luffy Maximilian, Eckstein Anja, Lahner Harald, Schittkowski Michael, Horn Maren, Lagrèze Wolf A, Bleul Tim, Pitz Susanne, Vorländer Christian, Pieterse Christelle C, Porter Brian, Clemens Andreas, Draikiwicz Steven, Reinhardt Maximilian, Kahaly George J. Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.. The Journal of clinical endocrinology and metabolism. 2026. DOI: 10.1210/clinem/dgaf655.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.